Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
about
Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphomaCustomized targeted therapy in Hodgkin lymphoma: hype or hope?Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplantBrentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studiesDiagnostic, prognostic and therapeutic role of CD30 in lymphoma.GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesBrentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphomaBrentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia.Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation.Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment.Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK centerCD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trialsImpact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.Brentuximab vedotin treatment for primary refractory hodgkin lymphoma.Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplRole of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.Advances in the treatment of Hodgkin lymphoma.Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.CD30 as a therapeutic target for lymphoma.Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!An update on emerging drugs for Hodgkin lymphoma.Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.The role of allogeneic stem cell transplantation in Hodgkin's lymphoma.Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.Brentuximab vedotin for the treatment of Hodgkin's lymphoma.The GHSG Approach to Treating Hodgkin's Lymphoma.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.
P2860
Q26772848-7D8D7F3D-CAB0-4BBF-9223-0122483D1872Q27002554-1E91734C-532D-4BB8-9621-348375810628Q27022992-FB7A7E71-574E-423C-A502-4DA622697392Q28087540-334EF37E-C9F8-4D59-8D30-D965EBBAD90CQ30240160-555F0322-8BC5-46C8-B977-E928C7891532Q33411127-F219072B-654D-4274-8C21-B7D296D6D6D0Q33886267-A666E815-6F05-4076-BEF2-F952EE071457Q34325201-EE7DB0A1-3DDE-4444-A644-FA3B3822FA7EQ34337660-E9F6A8EA-8DF4-44DD-8A8A-341AA963EF5BQ34655256-930127C1-C889-4A80-8C62-2C7F56AC295BQ35050554-452F7FB9-CDEE-44CB-BF75-C39465EB4940Q35103536-AE3D8F45-E866-4D6F-A638-15619BCBC866Q35865599-458BE47E-6F4D-4E05-A11A-4A92810D3012Q36264723-3428DC71-52B4-42FB-BDEF-78FC0F5CD285Q36794316-1E423F78-F487-4C27-A2FB-8FBE56EB6ADFQ36862523-0B103098-ED15-4642-9584-134599A578D7Q36979534-02F5D469-5429-4577-A255-E3266BD0FFBBQ37060652-F8BBFDA4-25AC-4D12-9BD0-C45881B1BD8FQ37216260-76148D31-6D35-49C2-8961-0A0EF2589908Q37254777-5BADEE53-7395-4C95-8966-6CDD8735EDBCQ37412853-72680575-E862-49B3-8676-58ECC2CA5000Q37530611-A1E9156B-92DD-4AE1-9097-62E25E8F2E7AQ37609957-A2DB3789-73E7-42D5-BD6D-B0D79BF70441Q37649035-0565D8FF-3876-49E8-A626-50088024C0E7Q38051197-BF1DA043-E2AB-40C4-8EEB-1B57D64DC3AAQ38066586-C6FE8ED1-DB7A-4ABF-80F4-03DEE6DDF101Q38073207-B8CAEFF6-7ECB-472D-AF1F-D566FB96FDACQ38131563-9F0C31E4-701E-4162-B778-8C4E8070E62DQ38138482-AF0B27D7-A696-4ABE-AD7E-80EB05DC08C1Q38164572-5BD63F55-319E-4CE7-BFAB-A47C2C05BDF8Q38179975-4621E7BE-3914-4FF0-85F5-117AC1757A0AQ38205874-61FB735F-FF50-4D3B-BDD8-7F4539D95B46Q38205923-73EA12AB-4C61-48C5-9BFC-77C3D9E003E0Q38206138-E9035F5C-1BF1-4165-99E1-FDCD3B52D582Q38227567-CBEF559D-9D9A-4DC1-903D-CDAE612B34DFQ38361620-05819BA5-6CA0-4D9E-A0B2-26CC745D7B10Q38476250-2EB844E3-2672-4CE3-A62B-FEBF90FE373DQ38506223-95907311-0460-4794-9896-1F9A97AAD51AQ38664909-80C073C1-BD12-48CF-91FF-3E7BE1CED940Q38700459-CDED2C9C-5A60-4D92-9E4A-CC85E8958DC7
P2860
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Brentuximab vedotin enables su ...... or refractory Hodgkin lymphoma
@ast
Brentuximab vedotin enables su ...... or refractory Hodgkin lymphoma
@en
type
label
Brentuximab vedotin enables su ...... or refractory Hodgkin lymphoma
@ast
Brentuximab vedotin enables su ...... or refractory Hodgkin lymphoma
@en
prefLabel
Brentuximab vedotin enables su ...... or refractory Hodgkin lymphoma
@ast
Brentuximab vedotin enables su ...... or refractory Hodgkin lymphoma
@en
P2093
P2860
P1433
P1476
Brentuximab vedotin enables su ...... or refractory Hodgkin lymphoma
@en
P2093
Ajay K Gopal
Auayporn Nademanee
Joycelynne M Palmer
Ni-Chun Tsai
Robert Chen
Sandra H Thomas
Stephen J Forman
P2860
P304
P356
10.1182/BLOOD-2012-03-418673
P407
P577
2012-05-18T00:00:00Z